PrEP use in the “real world”: Results from the iPrEX open label extension

red_ribbon-229x300Pre-exposure prophylaxis (PrEP) is an HIV prevention strategy that involves HIV-negative people taking anti-HIV drugs to reduce their risk of HIV infection. This strategy also involves regular visits with a service provider to test for HIV and other sexually transmitted infections (STIs), monitor side effects and receive adherence and risk-reduction support. Several randomized, placebo-controlled clinical trials (RCTs) have shown that the daily use of a pill containing the anti-HIV drugs tenofovir and FTC (known by the brand name Truvada) is generally safe and can reduce the risk of HIV infection by over 90% if taken as directed. It is less effective if pills are missed. The daily use of Truvada as PrEP has been approved by the Food and Drug Administration (FDA) in the U.S. Also, the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have released guidelines recommending that PrEP be offered to HIV-negative people at high risk of HIV infection.

continue reading / weiterlesen / ادامه مطلب